| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1a data readout example | Anzu-cel (anzutresgene autoleucel / IMA203) Multiple advanced solid tumors including melanoma, ovarian carcinoma, synovial sarcoma — dose escalation outcomes and RP2D determination | Phase 1a | — | Subscribe to access the data. | Cell Therapies | Oncology | |
Phase 1a data readout example | Anzu-cel (anzutresgene autoleucel / IMA203) Multiple advanced solid tumors including melanoma, ovarian carcinoma, synovial sarcoma — dose escalation outcomes and RP2D determination | Phase 1a | — | Subscribe to access the data. | Cell Therapies | Oncology | |
Phase 1a data readout example | Anzu-cel (anzutresgene autoleucel / IMA203) Multiple advanced solid tumors including melanoma, ovarian carcinoma, synovial sarcoma — dose escalation outcomes and RP2D determination | Phase 1a | — | Subscribe to access the data. | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Immatics N.V.$9.68
-0.28 (-2.81%)
C 58Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.56 B
EPS
-1.97
P/E Ratio
-
Value Trade
5.49 M
4.68 %
Week
2.83 %
1 Month
15.16 %
3 Month
15.28 %
6 Month
5.64 %
5 Year
22.32 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
264.07 K
52 Week Range
4.93 - 12.41
% held by Insiders
16.33 %
% held by Institutions
78.08 %
Enterprise Value
1.05 B
Total Shares
134.06 M
Short %
5.03 %
Float Shares
102.83 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immatics N.V.
228Total events
15Upcoming
75Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 15
Event history 213
Q3 2026
◆Dose Finding UpdateIMA402Trial
RP2D determination and clinical data update for IMA402 expected in 2H 2026
melanoma and gynecologic cancerssource ↗
Jun 1, 2026
◆Oral PresentationIMA203Presentation
Patient-level clinical response dynamics in advanced melanoma with anzu-cel
advanced cutaneous and uveal melanomasource ↗
Jun 1, 2026
▲Full ResultsIMA203Clinical Data
Extended Phase 1b data for anzu-cel released at ASCO 2026
metastatic melanomasource ↗
Jun 1, 2026
◆Oral PresentationIMA203Presentation
Oral presentation: Patient-level clinical response dynamics in advanced melanoma with anzu-cel
advanced melanomasource ↗
May 31, 2026
◆Oral PresentationIMA203CD8Presentation
Phase 1 study results with PRAME-directed TCR T-cell therapies in synovial sarcoma
synovial sarcomasource ↗
May 31, 2026
◆Oral PresentationIMA401Presentation
First-in-human results with IMA401, a MAGEA4/8 targeted TCER
recurrent or refractory solid tumorssource ↗
May 31, 2026
▲PublicationIMA401Presentation
Simultaneous publication of IMA401 Phase 1 results in Nature Medicine
solid tumorssource ↗
May 31, 2026
◆Oral PresentationPresentation
Oral presentation: Phase 1 study results with PRAME-directed TCR T-cell therapies in synovial sarcoma
synovial sarcomasource ↗
May 30, 2026
◆Oral PresentationIMA203CD8Presentation
Oral presentation: Phase 1a study results for IMA203CD8 in ovarian cancer
ovarian cancersource ↗
Drug Pipeline Intelligence
C58
Pipeline Score $1.8B
Pipeline ValueFair Value
Valuation Signal13
Drugs Scored1.1x
rNPV / MCap Top 85%
Micro Cap (rank 138 of 911)
Percentile RankImmatics N.V. carries a moderate pipeline score (58/100), with $4.8B risk-adjusted pipeline value, led by IMA203 in Melanoma, Cutaneous Malignant (Phase 3), across $166B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMA203 Monoclonal antibody | Melanoma, Cutaneous Malignant | Phase 3 | NCT06743126 | 60% | $1.3B | RECRUITING | 360 | AVERAGE | C (53) | Oct 1, 2031 | LOW_RISK | LOW Jun 10, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
anzu-cel | metastatic melanoma | Phase 1b | 2026-06-01 | confirmed ORR: 56%; m DOR: 14.6 months; m PFS: 6.1 months; m OS: 16.2 months Read More | Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting Read More | |
anzu-cel | metastatic melanoma | Phase 1b | 2026-06-01 | confirmed ORR: 56%; m DOR: 14.6 months; m PFS: 6.1 months; m OS: 16.2 months Read More | Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting Read More | |
anzu-cel | metastatic melanoma | Phase 1b | 2026-06-01 | confirmed ORR: 56%; m DOR: 14.6 months; m PFS: 6.1 months; m OS: 16.2 months Read More | Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 18, 2026 Edward Sturchio, General Counsel of Immatics N.V. (the Company ), opened the annual general meeting of the Company (the Meeting ) and d
The annual general meeting of shareholders of Immatics N.V. took place where General Counsel Edward Sturchio opened the meeting. The meeting was conducted in line with Dutch law and the company’s articles of association, with approximately 64.07% of the issued share capital represented. There were no comments or questions from shareholders during the meeting, allowing the agenda items to proceed directly to voting. All agenda items passed with the necessary majority votes.
Read more →IMTX▼ -9.9%on this news
CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register und
Immatics N.V. has issued a convening notice for its Annual General Meeting (AGM) scheduled for June 18, 2026, in Amsterdam. The notice details the required procedures for shareholders to attend or vote at the meeting, including deadlines for Attendance Notices and proxy submissions. Shareholders must meet specific criteria based on ownership and record dates to participate. Additional information related to the AGM is available on the company's official website.
Read more →IMTXImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics presented promising data on anzu-cel, a PRAME cell therapy, at the 2026 ASCO Annual Meeting. The therapy showed a 56% confirmed overall response rate and durable anti-tumor activity in metastatic melanoma patients. With manageable tolerability, anzu-cel is advancing towards a Phase 3 trial and potential BLA submission in early 2027.
Read more →IMTXImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Immatics presented promising data on IMA401, a TCR bispecific targeting MAGEA4/8, at the 2026 ASCO Annual Meeting. The treatment showed deep and durable responses in various cancers, including melanoma and head and neck cancer, with a notable initial signal in lung cancer. The data support the development of a combination therapy with IMA402, which is currently enrolling patients for a Phase 1 trial.
Read more →IMTXImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1
Immatics N.V. has presented updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy, which shows notable clinical activity in hard-to-treat gynecologic cancers and synovial sarcoma at the 2026 ASCO Annual Meeting. The therapy demonstrated anti-tumor activity with a one-time infusion showing promise in patients with limited treatment options. The company plans to broaden the evaluation of IMA203CD8 to additional PRAME-positive solid tumors based on the encouraging results so far.
Read more →IMTXImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. presented promising Phase 1 data for its IMA203CD8 PRAME cell therapy at the 2026 ASCO Annual Meeting. The therapy showed significant anti-tumor activity in hard-to-treat gynecologic cancers, achieving a 63% objective response rate in ovarian cancer. Additionally, it demonstrated durable responses in synovial sarcoma, with manageable tolerability. The company plans to expand its clinical evaluation into other PRAME-positive solid tumors.
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three-month period ended
Immatics N.V. reported its unaudited interim condensed consolidated financial statements for the three-month period ended March 31, 2026. The financial results indicate a significant net loss of €57,814,000, which is a substantial increase from the previous year's loss of €39,855,000. Research and development expenses also saw a notable rise, reflecting ongoing investments in product development. Additionally, the total comprehensive loss for the quarter was recorded at €55,939,000, compared to €42,566,000 in Q1 2025.
Read more →IMTXImmatics Announces First Quarter 2026 Financial Results and Business Update
Immatics N.V. reported its financial results for Q1 2026, highlighting significant progress in its clinical pipeline, particularly with the PRAME cell therapy, anzu-cel. The company anticipates multiple clinical data readouts in 2026 and is preparing for its first commercial launch in 2027. Despite a net loss of $66.5 million, Immatics maintains a strong cash position of $521.5 million.
Read more →IMTXImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting Houston, Texas and Tuebingen, Germany
Immatics N.V. has announced that all submitted abstracts will be presented at the 2026 ASCO Annual Meeting, focusing on its clinical cell therapy and bispecific programs. The presentations will feature data on various therapies targeting PRAME, which is expressed in over 50 types of cancer. This showcases the advancement of Immatics' PRAME franchise and emphasizes its commitment to developing innovative immunotherapies. The meeting is set to take place in Chicago from May 29 to June 2, 2026.
Read more →IMTXImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Immatics N.V. announced that all its submitted abstracts have been selected for oral presentations at the 2026 ASCO Annual Meeting. The presentations will cover clinical data on its lead PRAME cell therapy, an updated dose-escalation study for a second-generation candidate, and results from bispecific therapies. These findings highlight the company's commitment to advancing immunotherapies for solid tumors.
Read more →IMTXPRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma Individual experimental treatment attempt at Hopp Children's C
Immatics N.V. reported a significant case where a 17-year-old patient with advanced nephroblastoma experienced deep remission after receiving the company's PRAME-directed T-cell receptor therapy. The treatment was a last-ditch effort after other options had failed. With thorough monitoring, positive results included marked tumor regression and the absence of tumor-derived DNA in subsequent tests. This case highlights the potential of PRAME-targeted cell therapies for pediatric cancers.
Read more →IMTXPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Immatics announced a successful case of PRAME-directed TCR T-cell therapy in a 17-year-old with advanced nephroblastoma. The patient, having exhausted all treatment options, achieved deep remission with ongoing positive results at six months. This case underscores the potential of PRAME-targeted therapies in pediatric oncology, with plans for further clinical evaluations.
Read more →IMTXImmatics Announces Full Year 2025 Financial Results and Business Update
Immatics reported its full-year 2025 financial results, highlighting progress in its PRAME cell therapy programs, particularly anzu-cel, which is in a Phase 3 trial for advanced melanoma. The company expects to submit a BLA in the first half of 2027, with commercial launch anticipated in the second half of 2027. Despite a net loss of $230.8 million, Immatics maintains a strong cash position to support ongoing development.
Read more →IMTXImmatics Announces Full Year 2025 Financial Results and Business Update Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously tr
Immatics N.V. has reported its financial results and business updates for the year ending December 31, 2025. The company is advancing its lead PRAME cell therapy, anzu-cel (IMA203), towards approval while also exploring second-generation therapies and bispecifics. Despite a significant net loss and decline in total revenue compared to the previous year, Immatics has a solid cash reserve of $551.4 million. The company is focused on expanding the reach of its PRAME therapies to better address advanced cancers.
Read more →IMTXImmatics. Not for further reproduction or distribution. Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation
Immatics N.V. presented information regarding its corporate strategy and clinical pipeline, emphasizing its focus on the PRAME protein as a target for cancer therapies. The presentation highlights the company’s leadership in precision targeting and describes the various clinical product candidates under development. It also outlines the risks associated with forward-looking statements and the inherent uncertainties in predicting future performance. Immatics aims to advance its strategy through partnerships and clinical trials across multiple cancer types.
Read more →IMTXImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Immatics presented updated Phase 1a data for its IMA203CD8 PRAME cell therapy at the ESMO-IO 2025 Congress. The therapy showed promising initial anti-tumor activity in heavily pre-treated patients with solid tumors expressing PRAME. Notably, the treatment demonstrated manageable tolerability and deep objective responses, including complete responses in some patients. The company aims to continue dose escalation and further evaluate the therapy's potential in various cancers.
Read more →IMTXImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress IMA203CD8 is a second-gener
Immatics N.V. presented updated Phase 1a dose escalation data for its second-generation PRAME cell therapy, IMA203CD8, at the ESMO-IO 2025 Congress. The therapy demonstrated promising initial anti-tumor activity among heavily pre-treated patients with PRAME-positive tumors, including ovarian carcinoma. With manageable tolerability and durable responses observed, IMA203CD8 showcases potential benefits for patients who have limited treatment options. The ongoing trial aims to determine the recommended Phase 2 dose, leveraging the therapy's indication across solid tumors beyond melanoma.
Read more →IMTX▼ -14.2%on this news
Immatics Announces $125 Million Underwritten Offering Houston, Texas and Tuebingen, Germany
Immatics N.V. announced a $125 million underwritten offering of 12.5 million shares priced at $10.00 each. The proceeds from this offering are intended to support the company's commitment to advancing its precision targeting of PRAME, a target relevant in over 50 cancers. The offering is set to close on December 8, 2025, pending customary closing conditions. Immatics is at the forefront of developing therapies associated with this innovative biopharmaceutical strategy.
Read more →IMTX▼ -14.2%on this news
Immatics Announces $125 Million Underwritten Offering
Immatics Announces $125 Million Underwritten Offering
Read more →IMTX▼ -7.2%on this news
PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended
Immatics N.V. reported significant financial losses in its unaudited interim condensed consolidated financial statements for the periods ending September 30, 2025. The company experienced a net loss of €160,749, up from €25,537 in the previous year. Operating results also displayed a disappointing trend with a loss of €143,135, marking a notable decline. Additionally, the total assets of the company decreased from €696,146 at the end of 2024 to €518,557 as of September 30, 2025.
Read more →IMTX▼ -7.2%on this news
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Immatics Announces Third Quarter 2025 Financial Results and Business Update
Read more →IMTX▲ +16.1%on this newsshared move
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
Immatics N.V. has announced promising Phase 1a data for its TCR Bispecifics pipeline, specifically IMA402 and IMA401, demonstrating clinical proof-of-concept. The company reported favorable tolerability and deep, durable responses in advanced solid tumors. Next steps include advancing IMA402 into Phase 1b trials and exploring combinations with immune checkpoint inhibitors.
Read more →IMTX▲ +16.1%on this newsshared move
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER ) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps Company to host conf
Immatics has reported promising clinical proof-of-concept for its TCR Bispecific pipeline, particularly for product candidates IMA402 and IMA401. Updated Phase 1a data shows favorable safety and significant anti-tumor activity in heavily pretreated patients with limited treatment options. The company is set to expand clinical development, exploring combination therapies to enhance efficacy. The next phase of trials aims to address significant unmet needs in various cancer types.
Read more →IMTXImmatics Appoints Amie Krause as Chief People Officer
Immatics N.V. has appointed Amie Krause as Chief People Officer, effective October 27, 2025. With over 20 years of experience in HR, she will focus on organizational development as the company prepares for commercialization. Krause's previous roles include leadership positions at Dompé and Revance Therapeutics, and she aims to foster a culture of excellence at Immatics.
Read more →IMTXImmatics Appoints Amie Krause as Chief People Officer Houston , Texas and Tuebingen, Germany
Immatics N.V. has announced the appointment of Amie Krause as its Chief People Officer effective October 27, 2025. With over two decades of experience in human resources within the biopharmaceutical sector, Krause will focus on human resources as the company moves towards commercialization. CEO Harpreet Singh highlighted her capability in aligning talent with strategic business objectives. Krause's role is seen as crucial for enhancing organizational development and operational efficiency during this key transition for the company.
Read more →IMTX▲ +7.5%on this news
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
Immatics presented updated data on anzu-cel PRAME cell therapy for metastatic uveal melanoma at the ESMO Congress 2025. The Phase 1b trial showed significant anti-tumor activity, with a median shrinkage of liver lesions by 49.6%. The company plans to initiate a Phase 2 cohort to further explore this therapy's potential in treating patients with limited options.
Read more →IMTX▲ +11%on this newsshared move
Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium One-time infusion of anzu-cel (anzutresgene autoleucel,
Immatics presented updated data regarding their anzu-cel PRAME cell therapy at the ESMO 2025 Presidential Symposium. The therapy showed compelling anti-tumor activity in a trial involving 16 patients suffering from metastatic uveal melanoma. Results indicated significant tumor shrinkage in liver lesions and overall favorable tolerability. The company is set to expand its trials based on these promising outcomes, indicating a potential shift in treatment for this difficult-to-treat patient population.
Read more →IMTX▲ +5.6%on this news
Immatics Appoints Venkat Ramanan as Chief Financial Officer
Immatics N.V. has appointed Venkat Ramanan, Ph.D., as its new Chief Financial Officer. Ramanan brings over 25 years of experience in the biopharmaceutical sector, having held leadership roles at notable companies like Seagen and Gilead Sciences. His expertise is expected to facilitate the advancement of Immatics' PRAME franchise and support the commercialization of their cell therapy, anzu-cel.
Read more →IMTX▲ +5.6%on this newsshared move
Immatics Appoints Venkat Ramanan as Chief Financial Officer Houston , Texas and Tuebingen, Germany
Immatics N.V. has appointed Venkat Ramanan, Ph.D., as the new Chief Financial Officer, effective immediately. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously held leadership positions at notable companies such as Seagen and Gilead Sciences. His expertise in guiding successful product launches and facilitating corporate transactions aligns with Immatics' goal of advancing its PRAME cell therapy, anzu-cel, towards commercialization for patients with metastatic melanoma. The appointment signifies a strategic move for Immatics as it aims to strengthen its position in the precision targeting of PRAME.
Read more →IMTXImmatics Announces Second Quarter 2025 Financial Results and Business Update
Immatics N.V. reported its financial results for Q2 2025, highlighting positive Phase 1b data for its PRAME cell therapy, anzu-cel, aimed at advanced melanoma. The company is prioritizing the SUPRAME Phase 3 trial and plans to expand its PRAME franchise with new therapies. However, the financial report showed a significant net loss and decreased revenue compared to the previous year.
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month period ended
Immatics N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025. The report indicates a notable increase in net loss to €70.35 million for Q2 2025, nearly quadruple the loss reported in Q2 2024. Revenue from collaboration agreements is down significantly, while research and development expenses have risen sharply, raising concerns about the company's financial health and operational efficiency. The overall financial position shows a drop in total assets and an increase in liabilities, reflecting ongoing challenges in the company's business model.
Read more →IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 18, 2025 Edward Sturchio, General Counsel of Immatics N.V. (the Company ), opened the annual general meeting of the Company (the Meeting ) and d
The Annual General Meeting of Shareholders for Immatics N.V. was convened with significant shareholder participation, representing approximately 79.18% of the company's issued share capital. General Counsel Edward Sturchio opened the meeting, where no objections were raised by attending shareholders. All voting items on the agenda received the necessary majority and were passed successfully. The meeting was conducted in accordance with Dutch law and the company's bylaws.
Read more →IMTX▲ +11.5%on this news
CONVENING NOTICE OF THE ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register und
Immatics N.V. has issued a convening notice for its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Amsterdam. Shareholders of record and beneficial owners are invited to attend, provided they notify the company in advance. Necessary documentation and voting procedures have been outlined in the notice. All participants must comply with the specified requirements to gain admittance to the AGM.
Read more →IMTX▲ +11.5%on this newsshared move
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Immatics presented promising data from its Phase 1b trial of IMA203 PRAME cell therapy for metastatic melanoma at the 2025 ASCO Annual Meeting. The therapy showed a confirmed overall response rate of 56% and a favorable safety profile. The ongoing Phase 3 SUPRAME trial aims to further evaluate IMA203's efficacy in patients who have previously failed checkpoint inhibitors.
Read more →IMTX▲ +11.5%on this newsshared move
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma Extended Phase 1b trial follow-
Immatics N.V. presented promising data on its IMA203 PRAME cell therapy at the 2025 ASCO Annual Meeting, highlighting strong anti-tumor activity and durability in patients with metastatic melanoma. The Phase 1b clinical trial revealed a confirmed overall response rate of 56%, along with a favorable tolerability profile. The ongoing Phase 3 SUPRAME trial aims to further evaluate the therapy's efficacy in patients who have undergone prior checkpoint inhibitor treatment. The positive results reinforce Immatics' position in the development of innovative cancer immunotherapies targeting PRAME.
Read more →IMTXImmatics Announces First Quarter 2025 Financial Results and Business Update
Immatics Announces First Quarter 2025 Financial Results and Business Update
Read more →IMTXImmatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Immatics N.V. announced that it will present data on its IMA203 TCR T-cell therapy at the 2025 ASCO Annual Meeting. The presentations will include updated results from the Phase 1b trial in metastatic melanoma and a trial-in-progress poster for the ongoing Phase 3 SUPRAME trial. These updates reflect the company's advancements in cancer immunotherapy targeting PRAME.
Read more →IMTXImmatics Announces Full Year 2024 Financial Results and Business Update Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient
Immatics N.V. announced its financial results for the full year 2024, highlighting significant advancements in its clinical portfolio, notably the initiation of the SUPRAME Phase 3 trial for its lead TCR-T cell therapy, IMA203. This therapy targets patients with previously treated advanced melanoma and aims to achieve full approval through a randomized-controlled study that includes enrollment across multiple countries. Immatics also detailed its manufacturing capabilities and plans for future clinical data releases to showcase the efficacy of IMA203 and its next-generation therapies in treating various solid tumors.
Read more →IMTXImmatics Announces Full Year 2024 Financial Results and Business Update
Immatics Announces Full Year 2024 Financial Results and Business Update
Read more →IMTXDelivering the Power of T cells to Cancer Patients Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation
Immatics N.V. is enhancing its cancer treatment approach by expanding its PRAME cell therapy into earlier treatment lines and targeting additional solid tumors. The company's pipeline includes several anticipated milestones for clinical trials in various cancers, including melanoma and gynecologic cancers, with key data expected in 2025 and beyond. However, forward-looking statements highlight inherent risks and uncertainties affecting future outcomes. The ongoing Phase 3 SUPRAME trial indicates Immatics' strategic focus on advancing its therapeutic offerings within the oncology space.
Read more →IMTXImmatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month periods ended
Immatics N.V. has released its unaudited interim condensed consolidated financial statements for the three- and nine-month periods ending September 30, 2024. The report indicates a substantial increase in revenue from collaboration agreements compared to the previous year, although the company still reported a significant net loss. Key operational expenses, particularly in research and administration, have also risen, leading to losses before tax.
Read more →IMTXImmatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Read more →IMTXImmatics Announces Multiple Presentations at the 39 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME Two oral presentations and multiple poster
Immatics N.V. has announced multiple presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) focusing on their TCR-T therapy candidates targeting PRAME. The company has shared clinical data from ongoing trials, demonstrating encouraging results for their lead candidate, IMA203, and next-generation therapy IMA203CD8. They aim to expand their focus on additional solid tumors and are set to initiate a Phase 3 trial for IMA203 targeting metastatic melanoma in December. However, safety concerns related to side effects and dosing continue to be monitored.
Read more →IMTXImmatics Announces Pricing of $150 Million Public Offering
Immatics Announces Pricing of $150 Million Public Offering
Read more →IMTX▼ -15.6%on this newsshared move
Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial Company to host conference call and web
Immatics N.V. announced the updated Phase 1b clinical data for its ACTengine IMA203 TCR-T therapy targeting PRAME in melanoma patients, reporting promising efficacy with significant tumor shrinkage. The company is preparing to launch the SUPRAME Phase 3 trial, with a focus on progression-free survival as a primary endpoint, aligned with discussions held with the FDA. Notably, the trial will include heavily pretreated metastatic melanoma patients, and early data indicate a boost in both safety and efficacy outcomes. Overall, the updates reflect a positive trajectory for IMA203 in advancing towards regulatory approval.
Read more →IMTX▼ -15.6%on this newsshared move
Immatics Announces Proposed $150 Million Public Offering
Immatics Announces Proposed $150 Million Public Offering
Read more →IMTX▼ -15.6%on this newsshared move
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Read more →IMTX▼ -15.6%on this newsshared move
Immatics Announces Proposed $150 Million Public Offering Houston, Texas and Tuebingen, Germany
Immatics N.V. has announced a proposed public offering of $150 million aimed at advancing its cancer immunotherapy initiatives. The company focuses on the development of T cell-redirecting therapies and has begun the requisite filings with the SEC. The success of this offering is contingent on market conditions, which adds a layer of uncertainty. This move is expected to enhance Immatics' financial stability, enabling further development in its pipeline.
Read more →IMTXImmatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
Read more →IMTXImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
Read more →IMTXImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update TCER IMA4
Immatics N.V. has presented clinical proof-of-concept data for its TCR bispecific molecule TCER IMA401 at the ESMO Congress 2024. The ongoing Phase 1 trial suggests initial anti-tumor activity in heavily pretreated patients with solid tumors, demonstrating durable objective responses. However, the company announced that its development collaboration with Bristol Myers Squibb would be terminated, reverting all rights back to Immatics. Despite this, Immatics plans to advance IMA401 further through clinical development with the next data update expected in 2025.
Read more →IMTXImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
Read more →IMTXImmatics Announces Second Quarter 2024 Financial Results and Business Update
Immatics Announces Second Quarter 2024 Financial Results and Business Update
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and six-month periods ended
Immatics N.V. has released its unaudited interim consolidated financial statements for the six months ending June 30, 2024. The company reported a net loss of €21,076, significantly improved from a loss of €44,357 in the prior year. However, research and development costs increased considerably, raising concerns about financial sustainability. The report also includes various forward-looking statements about potential risks affecting their operations and strategies moving forward.
Read more →IMTXImmatics Appoints Alise Reicin to Board of Directors
Immatics Appoints Alise Reicin to Board of Directors
Read more →IMTXImmatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024
Read more →IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2024 Edward Sturchio, General Counsel of Immatics N.V. (the Company ), opened the annual general meeting of the Company (the Meeting ) and d
The annual general meeting of Immatics N.V. took place on June 20, 2024, with General Counsel Edward Sturchio presiding. A significant portion of the Company's issued share capital, approximately 81.36%, was represented at the meeting. The meeting proceeded without any questions or comments from shareholders regarding the agenda and all proposed voting items were passed by the requisite majority. Subsequently, the meeting was officially closed.
Read more →IMTX▲ +5.5%on this news
Immatics Announces First Quarter 2024 Financial Results and Business Update
Immatics Announces First Quarter 2024 Financial Results and Business Update
Read more →IMTX▼ -5.9%on this news
Immatics Announces Full Year 2023 Financial Results and Corporate Update Interim clinical data update on ACTengine IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with medi
Immatics N.V. recently announced its financial results for the year ended December 31, 2023, noting a net loss of $97 million. Despite the financial setbacks, the company reported promising clinical data for its IMA203 GEN1 therapy, demonstrating a 50% confirmed objective response rate in melanoma patients. With significant funding raised, Immatics plans to initiate a Phase 2/3 trial for IMA203 GEN1 in 2024, aiming for accelerated approval. Additionally, they continue to develop their second-generation therapy, IMA203CD8 GEN2, which has shown a 56% confirmed objective response rate.
Read more →IMTX▼ -7.4%on this news
Immatics Announces Pricing of $175 Million Public Offering
Immatics Announces Pricing of $175 Million Public Offering
Read more →IMTX▼ -7.4%on this news
P R E S S R E L E A S E Immatics Announces Proposed Public Offering Houston, Texas and Tuebingen, Germany
Immatics N.V. announced a proposed public offering of its ordinary shares as part of its efforts to advance its T cell-redirecting cancer immunotherapies. The offering is underwritten by Jefferies, BofA Securities, and Leerink Partners, although its completion is contingent upon market conditions. A preliminary prospectus has been filed with the SEC, but there are no guarantees regarding the final size or terms of the offering. This move reflects Immatics' ongoing commitment to developing effective treatments for cancer patients.
Read more →IMTX▼ -7.4%on this news
Immatics Announces Proposed Public Offering
Immatics Announces Proposed Public Offering
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three and nine-month periods ended
Immatics N.V. has released its interim condensed consolidated financial statements for the periods ended September 30, 2023. The report highlights a substantial net loss of €70,846 for the nine-month period, a stark contrast to the profit reported in the same period in 2022. The financial statements indicate increasing research and development expenses, emphasizing the company's ongoing investment in its pipeline despite the losses. Additionally, the report contains numerous forward-looking statements that recognize various risks that could impact future operational performance and financial condition.
Read more →IMTXImmatics Announces Third Quarter 2023 Financial Results and Business Update
Immatics Announces Third Quarter 2023 Financial Results and Business Update
Read more →IMTXImmatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Read more →IMTXImmatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial Company to host conference call and webcast today, November 8, at 8
Immatics has reported interim clinical data from its Phase 1 trial of the ACTengine IMA203 and IMA203CD8 TCR-T monotherapies, focusing on melanoma patients. The data shows a 50% confirmed objective response rate for IMA203 GEN1, while the new IMA203CD8 candidate demonstrated a 56% response rate. Immatics plans to progress IMA203 into a Phase 2 trial aiming for registration in melanoma and explore its potential in other cancer types. A conference call was scheduled for further discussion of these findings.
Read more →IMTXImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy
Read more →IMTXImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine IMA203 TCR-T Monotherapy RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressi
Immatics N.V. has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its ACTengine IMA203 TCR-T monotherapy program targeting various cancers expressing the PRAME protein. This designation highlights the promising potential of IMA203, which is currently being tested in patients with relapsed or refractory solid tumors. The RMAT status offers several advantages, including early discussions with the FDA on trial design and the possibility of expedited review processes. As the first oncology drug candidate to receive RMAT designation for more than two solid tumor indications, IMA203 marks a significant milestone in Immatics' development efforts.
Read more →IMTXModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Read more →IMTXModerna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo exp
Moderna and Immatics have entered into a strategic collaboration aimed at developing innovative oncology therapeutics utilizing their complementary technologies. The partnership will combine Immatics' T cell-redirecting therapies with Moderna's mRNA platforms, which could accelerate the development of cancer treatments. Immatics will receive an upfront payment of $120 million and has the potential to earn additional milestone payments surpassing $1.7 billion, contingent on the success of the collaboration. Each company will maintain ownership of their proprietary compounds, while both will share costs for clinical studies.
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month periods ended
Immatics N.V. released its unaudited consolidated financial statements for the three and six-month periods ending June 30, 2023, revealing a substantial net loss of €44.4 million. The report indicates an increase in research and development expenses while the overall financial situation has worsened compared to the previous year. The company continues to prepare for future regulatory submissions and ongoing clinical trials, highlighting the inherent risks and uncertainties associated with such forward-looking statements.
Read more →IMTXImmatics Announces Second Quarter 2023 Financial Results and Business Update
Immatics Announces Second Quarter 2023 Financial Results and Business Update
Read more →IMTXImmatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors TCER IMA402 is the first next-generation, half-life extended TCR Bispecific targeti
Immatics N.V. has announced the initiation of a Phase 1/2 clinical trial for its bispecific T cell engaging receptor, IMA402, targeting patients with advanced solid tumors expressing the PRAME antigen. The trial, which will initially enroll around 45 patients, aims to determine the maximum tolerated dose and assess safety and anti-tumor activity. It intends to leverage an adaptive design to accelerate development and plans to expand further into the US market as the trial progresses. IMA402 represents a strategic effort to harness the clinical potential of PRAME in cancer therapy.
Read more →IMTXImmatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
Read more →IMTXImmatics Announces $35 Million Equity Investment from Bristol Myers Squibb Tuebingen, Germany and Houston, TX
Immatics N.V. has announced a significant $35 million equity investment from Bristol Myers Squibb, with the purchase of 2,419,818 shares at a price of $14.461 each. This transaction highlights the strength of the relationship between the two companies and supports Immatics' focus on developing T cell-redirecting cancer immunotherapies. Bristol Myers Squibb's investment also grants them the right to appoint a member to Immatics' Scientific Advisory Board, indicating a deepening collaboration in advancing cancer treatments. Immatics aims to continue providing innovative treatment options for patients and will share further clinical results later this year.
Read more →IMTXImmatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Read more →IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 20, 2023 Edward Sturchio, General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and
The annual general meeting of shareholders for Immatics N.V. was held on June 20, 2023, and successfully convened with approximately 73% of the company's issued share capital represented. The meeting proceeded without questions or comments from shareholders, leading to a unanimous passage of all agenda items. The meeting was closed efficiently following the voting and is recorded by the company's legal representatives.
Read more →IMTXImmatics Announces First Quarter 2023 Financial Results and Business Update
Immatics Announces First Quarter 2023 Financial Results and Business Update
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three-month period ended
Immatics N.V. released its unaudited consolidated financial statements for Q1 2023, reporting a significant loss of €19.7 million compared to a profit of €85.7 million in Q1 2022. The total assets of the company decreased to €378.5 million from €407.8 million at the end of 2022. The financial results reflect increasing research and development expenses, contributing to the net loss. The company continues to face various operational challenges that may impact future financial performance.
Read more →IMTX▲ +27.5%on this news· ran to +38% by day 3
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME
Read more →IMTX▲ +27.5%on this news· ran to +38% by day 3
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Upda
Immatics N.V. reported interim clinical data from their Phase 1b study of ACTengine IMA203 TCR-T therapy targeting PRAME in patients with recurrent solid tumors. The monotherapy demonstrated a 67% confirmed objective response rate among treated patients, with several achieving responses lasting over 9 months. The treatment had manageable tolerability with no serious adverse effects observed, presenting a promising option for patients with limited treatment choices. Immatics anticipates further developments, including a potential fast-to-market approach for specific indications by the end of the year.
Read more →IMTXImmatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Read more →IMTXImmatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration Bristol Myers Squibb exercised its first option and entered into a global license ag
Immatics N.V. announced that Bristol Myers Squibb has exercised its first option to license a T cell receptor engineered therapy from their ongoing strategic collaboration. This agreement expands on a previous partnership aimed at developing TCR-T therapies for cancer treatment. As part of the collaboration, Immatics is eligible for milestone payments totaling up to $505 million, alongside royalties on net sales. The opt-in reflects confidence in Immatics' capabilities and the potential impact of these therapies on cancer patients.
Read more →IMTXImmatics Announces Full Year 2022 Financial Results and Corporate Update ACTengine IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid can
Immatics N.V. reported its full year 2022 financial results, showcasing a positive performance with a notable confirmed objective response rate from its ACTengine IMA203 TCR-T monotherapy targeting PRAME. The company increased its cash reserves significantly, providing financial stability to support ongoing and future projects. Additionally, Immatics is establishing a new GMP cell therapy manufacturing facility to enhance production capacity for its therapies. However, the IND submission for its IMA204 candidate has been delayed, and R&D expenses have seen an upward trend reflecting the company's clinical advancements.
Read more →IMTX▼ -8.7%on this news
Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation
Immatics N.V. presents its corporate strategy highlighting the development of TCR-based therapies targeting solid tumors. The company outlines two clinical-stage modalities: TCR-T and TCR Bispecific product candidates. Notable advancements include promising response rates in early clinical trials and a solid pipeline for 2023. However, the associated risks and uncertainties related to future performance and market conditions are acknowledged.
Read more →IMTXImmatics Announces Third Quarter 2022 Financial Results and Business Update
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month periods ended
condensed Consolidated Financial Statements for the three and nine-month periods ended September 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ( Interim Financial Reporting ), as issued by the International Accounting Stand
Read more →IMTXNext-Generation TCR Bispecifics (TCER) Targeting Peptide-HLA Antigens for the Treatment of Patients with Solid Tumors S. Bunk1, M. Hofmann1, G. Pszolla1, F. Schwoebel1, M. Hutt1, F. Unverdorben1, N. Aschmoneit1, M. M lh
Next - Generation TCR Bispecifics (TCER) Targeting Peptide - HLA Antigens for the Treatment of Patients with Solid Tumors S. Bunk 1 , M. Hofmann 1 , G. Pszolla 1 , F. Schwoebel 1 , M. Hutt 1 , F. Unverdorben 1 , N. Aschmoneit 1 , M. M lh j 1 , C. Wagner 1 , M. Jaworski 1 , C. Sch
Read more →IMTX▲ +11.6%on this news
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares Houston, Texas and Tuebingen, Germany
Announces $110 Million Underwritten Offering of Ordinary Shares Texas and Tuebingen, Germany, October 10, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunother
Read more →IMTX▲ +11.6%on this news
Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PR
Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Texas and Tuebingen, Germany, October 10, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biop
Read more →IMTX▲ +11.6%on this news
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
Read more →IMTX▲ +11.6%on this news
Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME
Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME
Read more →IMTX▼ -15.2%on this news
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 TCER IMA402 is a next-generation, half-
Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Tuebingen, Germany and Houston, Texas, September 10, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stag
Read more →IMTX▼ -15.2%on this news
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
Read more →IMTXImmatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME
Read more →IMTXImmatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME IMA203CD8 is a 2 nd -generation product candidate co-expressing Immatics' proprieta
Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME Texas and Tuebingen, Germany, August 23, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and d
Read more →IMTXImmatics Announces Second Quarter 2022 Financial Results and Business Update
Immatics Announces Second Quarter 2022 Financial Results and Business Update
Read more →IMTXImmatics. Not for further reproduction or distribution. Immatics Corporate Presentation
Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation June 30, 2022 Forward - Looking Statements 2 This presentation ("Presentation") is provided by Immatics N . V . ("Immatics" or the "Company") for informational purposes only . The information
Read more →IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 13, 2022 Edward Sturchio, General Counsel of Immatics N.V. (the Company ), opened the annual general meeting of the Company (the Meeting ) and d
ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. General Counsel of Immatics N.V. (the "Company"), opened the annual general meeting of the Company (the "Meeting") and designated Paul van der Bijl, civil law notary of NautaDutilh N.V., the Company's Dutch legal counsel,
Read more →IMTXImmatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, I
Read more →IMTXImmatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer Tuebingen, Germ
Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer Houston, Texas; and Cambridge, Mass., June 7, 2022 - Immatics N.V. (Nasdaq: IMTX, "Immatics"), a clinical-s
Read more →IMTXImmatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together
and Bristol Myers Squibb Expand Strategic Alliance Gamma Delta Allogeneic Cell Therapy Programs Houston & New York - June 2, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti
Read more →IMTXImmatics Announces First Quarter 2022 Financial Results and Business Update
Immatics Announces First Quarter 2022 Financial Results and Business Update
Read more →IMTXImmatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
Read more →IMTXImmatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Immatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Read more →IMTXImmatics Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors The Phase 1b dose expansion cohort wil
Announces First Patient Treated with ACTengine IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo (nivolumab) in Patients with Advanced Solid Tumors Texas and Tuebingen, Germany, May XX, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceut
Read more →IMTXImmatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Read more →IMTXImmatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany
Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors Tuebingen, Germany and Houston, Texas, May 10, 2022 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery an
Read more →IMTXImmatics Announces Full Year 2021 Financial Results and Corporate Update
Immatics Announces Full Year 2021 Financial Results and Corporate Update
Read more →IMTXImmatics Announces Full Year 2021 Financial Results and Corporate Update IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim up
Immatics Announces Full Year 2021 Financial and Corporate Update Germany and Houston, TX, March 23, 2022 - Immatics N.V. (NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies,
Read more →IMTX▲ +8.9%on this news
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401
Read more →IMTX▲ +8.9%on this news
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401 Bristol Myers Squibb secures global exclusive license to Immatics' TCR bispecific program IM
and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401 Houston & New York - December 14, 2021 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T c
Read more →IMTXImmatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and nine-month periods ended
condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2021, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IAS
Read more →IMTX▼ -13.9%on this news
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Read more →IMTX▼ -13.9%on this news
Immatics. Not for further reproduction or distribution. ACTengine IMA200 TCR - T Programs Interim Phase 1a Update Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer
Immatics. Not for further reproduction or distribution. ACTengine IMA200 TCR - T Programs Interim Phase 1a Update Cedrik Britten, Chief Medical Officer Harpreet Singh, Chief Executive Officer November 09, 2021 Additional late - breaking oral presentation at SITC Annual Meeting on
Read more →IMTXImmatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual Meeting
Immatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual Meeting
Read more →IMTXImmatics to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual Meeting Houston, Texas and Tuebingen, Germany , November 1 , 2021 - Immat
to Present Update on Lead ACTengine Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer's 36th Annual Meeting Texas and Tuebingen, Germany, November 1, 2021 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three- and six-month periods ended
condensed Consolidated Financial Statements for the three- and six-month periods ended June 30, 2021, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). T
Read more →IMTXImmatics Announces Second Quarter 2021 Financial Results and Provides Business Update
Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update
Read more →IMTXImmatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, July 2021 Forward - Looking Statements 2 This presentation ("Presentation") is
Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, July 2021 Forward - Looking Statements 2 This presentation ("Presentation") is provided by Immatics N . V . ("Immatics" or the "Company")
Read more →IMTXBioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions
Read more →IMTXImmatics N.V. Annual General Meeting of Shareholders
Annual General Meeting of Shareholders June 17, 2021 - 2:00 p.m. CEST MINUTES of the proceedings at the annual general meeting of Immatics N.V., a public company under Dutch law, having its seat in Amsterdam, the Netherlands, and its address at Paul-Ehrlich-Strasse 15, 72076
Read more →IMTXImmatics Announces Changes to its Board of Directors Tuebingen, Germany and Houston, Texas , May 26 , 2021 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in th
Announces Changes to its Board of Directors Germany and Houston, Texas, May 26, 2021 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced cha
Read more →IMTXImmatics Announces Changes to its Board of Directors
Immatics Announces Changes to its Board of Directors
Read more →IMTXImmatics Announces First Quarter 2021 Financial Results and Business Update
Immatics Announces First Quarter 2021 Financial Results and Business Update
Read more →IMTXImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME Immatics' second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete r
Immatics Presents Preclinical Proof-of-Concept TCR Bispecifics Program IMA402 Targeting PRAME Tuebingen, Germany and Houston, Texas, May 11, 2021 - Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of
Read more →IMTXImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME
Read more →IMTXImmatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, April 2021 Forward - Looking Statements 2 This presentation ("Presentation") is
Immatics. Not for further reproduction or distribution. Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, April 2021 Forward - Looking Statements 2 This presentation ("Presentation") is provided by Immatics N . V . ("Immatics" or the "Company")
Read more →IMTXImmatics Announces Full Year 2020 Financial Results and Corporate Update Phase 1a data update from clinical ACTengine programs demonstrated first anti-tumor activity at early phases of dose escalation in he
Immatics Announces Full Year 2020 Financial and Corporate Update Germany and Houston, TX, March 30, 2021 - Immatics N.V. (NASDAQ: IMTX; "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies,
Read more →IMTXImmatics Announces Full Year 2020 Financial Results and Corporate Update
Immatics Announces Full Year 2020 Financial Results and Corporate Update
Read more →IMTXImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs
Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs
Read more →IMTXImmatics Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs Company to host conference call on Wednesday, March 17 at 8:30 am EST First anti-tumor activity observed in heav
Presents Data Update on Dose Escalation from Ongoing ACTengine Cell Therapy Programs to host conference call on Wednesday, March 17 at 8:30 am EST Texas and Tuebingen, Germany, Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in th
Read more →IMTXForward-Looking Statement This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusi
Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, January 2021 Exhibit 99.1 Forward-Looking Statement This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The informati
Read more →IMTXImmatics Announces Third Quarter 2020 Financial Results and Business Update
Immatics Announces Third Quarter 2020 Financial Results and Business Update
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month period ended
condensed Consolidated Financial Statements for the three and nine-month period ended September 30, 2020, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB
Read more →IMTXImmatics Presents Phase I Data from ACTolog Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
Immatics Presents Phase I Data from ACTolog Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
Read more →IMTXImmatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
Read more →IMTXImmatics Appoints Arnd Christ as Chief Financial Officer Tuebingen , Germany and Houston, Texas, September 29 , 2020 Immatics N.V. (NASDAQ: IMTX, Immatics ), a clinical-stage biopharmaceutical company activ
Immatics Appoints Arnd Christ as Chief Financial Officer Tuebingen, Germany and Houston, Texas, September 29, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunother
Read more →IMTXImmatics Appoints Arnd Christ as Chief Financial Officer
Immatics Appoints Arnd Christ as Chief Financial Officer
Read more →IMTXImmatics Appoints Biotech Executive Eliot Forster to Board of Directors
Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
Read more →IMTXImmatics Appoints Biotech Executive Eliot Forster to Board of Directors Tuebingen, Germany and Houston, Texas
Immatics Appoints Biotech Executive Eliot Forster to Board of Directors Tuebingen, Germany and Houston, Texas, September 15, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca
Read more →IMTXImmatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment IMA204 ACTengine cell therapy program directed at novel tumor target COL6A3 exon 6 prevalently expresse
Immatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment Tuebingen, Germany and Houston, Texas, September 10, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics ), a clinical-stage biopharmaceutical company active in the discovery and deve
Read more →IMTXImmatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment
Immatics Provides Update on IMA204 ACTengine Cell Therapy Program Targeting the Tumor Microenvironment
Read more →IMTXPRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-month period ended
condensed Consolidated Financial Statements for the three and six-month period ended June 30, 2020, included herein, have been prepared in accordance with International Financial Reporting Standards ( IFRS ) as issued by the International Accounting Standards Board ( IASB ). The
Read more →IMTXImmatics Announces Second Quarter 2020 Financial Results and Business Update
Immatics Announces Second Quarter 2020 Financial Results and Business Update
Read more →IMTXImmatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs First patient has been treated in Germany in Immatics ACTengine IMA202-101 trial German regulatory agency, Paul-Ehrlich-I
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs Tuebingen, Germany and Houston, Texas, August 18, 2020 Immatics N.V. (NASDAQ: IMTX, Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell red
Read more →IMTXImmatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
Read more →IMTXImmatics Extends Cell Therapy Manufacturing Collaboration with UTHealth Extension of collaboration between UTHealth and Immatics until end of 2024 providing Immatics exclusive access to state-of-the art cGM
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth Houston, Texas, August 6, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, toda
Read more →IMTXImmatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
Read more →IMTXImmatics Announces Board of Directors Additions Following Public Listing on NASDAQ
Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
Read more →IMTXImmatics Announces Completion of Business Combination and Listing on NASDAQ
Immatics Announces Completion of Business Combination and Listing on NASDAQ
Read more →IMTXImmatics Announces Completion of Business Combination and Listing on NASDAQ The business combination transaction with Arya Sciences Acquisition Corporation, a special purpose acquisition company sponsored b
Immatics Announces Completion of Business Combination and Listing on NASDAQ Houston, Texas and Tuebingen, Germany, July 2, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics ), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting can
Read more →IMTXImmatics and GSK Partner to Develop Novel Adoptive Cell Therapies
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
Read more →IMTXImmatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
Read more →IMTXGenmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies
Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies
Read more →IMTXImmatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Read more →IMTXImmatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse
Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse
Read more →IMTXAmgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Read more →IMTXImmatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies
Immatics and MD Anderson Announce Launch of Immatics US, Inc., to Develop Multiple T-cell and TCR-based Adoptive Cellular Therapies
Read more →IMTXEU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer
Read more →IMTXimmatics Receives EUR 22 Million Final Tranche of Series D Fundraising
immatics Receives EUR 22 Million Final Tranche of Series D Fundraising
Read more →IMTXimmatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration
immatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration
Read more →IMTXimmatics Closes EUR 34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer
immatics Closes EUR 34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer
Read more →IMTXNew EU-funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients
New EU-funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients
Read more →IMTXimmatics Appoints Peter Chambre as Chairman
immatics Appoints Peter Chambre as Chairman
Read more →IMTXimmatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA
immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA
Read more →IMTXimmatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival
immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival
Read more →IMTXimmatics Wins 2012 TiE50 Award
immatics Wins 2012 TiE50 Award
Read more →IMTXFirst Patients are Vaccinated in IMPRINT, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)
First Patients are Vaccinated in IMPRINT, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)
Read more →IMTXimmatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients
immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients
Read more →IMTXimmatics Raises EUR 54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
immatics Raises EUR 54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio
Read more →Competitive Position
How IMTX ranks across every disease it competes inCompetitive Position is a premium feature
See how IMTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial